research Estranys matins de febrer: Pauline Fondevila
Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.
Search
for
Sort by
Research
810-840 / 1000+ resultsresearch JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Clinical Trial of Finasteride on Alopecia X in a Dog
research Probing androgen receptor co-factor selectivity profiles: a chemical tool to determine cross-talk between androgen receptor and β-catenin in vivo
PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research NEW PROPRIETARY BRANDS: Cephalexin
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
research A combination of low-dose systemic etretinate and topical calcipotriol/betamethasone dipropionate treatment for hyperkeratosis and itching in Olmsted syndrome associated with a TRPV3 mutation
The combined treatment effectively managed severe skin issues in Olmsted syndrome.
research Severe alopecia areata treated with systemic corticosteroids
Systemic corticosteroids don't prevent severe alopecia areata from spreading or relapsing.
research Topical cyclosporine in male pattern alopecia
Topical cyclosporine led to significant hair growth in some men with male pattern baldness.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Influence of Different Designs of High-Heeled Shoes on Kinematics, Kinetics, and Muscle EMG of Female Gait
Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
research 63748 Combined Regenerative Technique: A New Therapeutical Option for Androgenetic Alopecia
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice.
Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series
Combining high-dose corticosteroids with methotrexate may be effective and safe for severe alopecia areata.
research Hair Growth Promoting and Anticancer Effects of p21-activated kinase 1 (PAK1) Inhibitors Isolated from Different Parts of Alpinia zerumbet
Compounds from Alpinia zerumbet may help with hair regrowth and cancer treatment by targeting PAK1.
research Randomized Therapeutic trial for patients with Alopecia Areata .
Topical minoxidil, intralesional steroids, and cryotherapy significantly improve alopecia areata.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
research Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
research Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience
Clascoterone cream 1% is effective and well-tolerated for treating acne and other related conditions.
research Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research AKT2 Gene Polymorphisms, sRANKL/OPG and Hormone Measurements in Polycystic Ovarian Syndrome (PCOS) Women
Certain gene variations in AKT2 are more common in women with PCOS and are linked to higher levels of specific hormones and symptoms.
research Management of adolescent polycystic ovary syndrome
SPIOMET therapy may be a promising alternative to oral contraceptives for treating adolescent PCOS.
research Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Off-Label Treatment of Alopecia Areata—Retrospective Study
Off-label treatments are heavily used for alopecia areata due to limited approved options.
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.